A CROSS-SECTIONAL STUDY ON SODIUM VALPROATE, CARBAMAZEPINE, AND LEVETIRACETAM INDUCING ENUREESIS IN EPILEPTIC CHILDREN

ARYA SATHYAN*, RESHMA SCARIA

Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, Tamil Nadu, India. Email: aryaps8891@gmail.com

Received: 19 August 2021, Revised and Accepted: 08 November 2021

ABSTRACT

Objectives: Enuresis or bedwetting is considered to be an underreported ADR of antiepileptic drugs (AEDs). This study assesses the incidence and comparative rate of occurrence of enuresis in children with epilepsy who are on AEDs treatment such as sodium valproate (SV); carbamazepine and levetiracetam (LEV).

Methods: The study was conducted with a sample size of 32 patients. Both inpatients and outpatients between the age group 5–18 years of age previously diagnosed with epilepsy that is on monotherapy and polytherapy with SV or carbamazepine or LEV were included in the study. Patients with urinary complications or urogenital abnormalities past 3 months before admission were excluded from the study. Assessment of enuresis was done based on a questionnaire prepared from NICE guidelines and analyzed using SPSS software version 20.

Results: Of 44 patients who were included in the study, only 34 came for review. Analysis of the questionnaire showed the occurrence of enuresis in 12 patients. Drugs prescribed versus assessment questions showed potent significance with eight questions; hence the hypothesis that the prescribed drugs can cause enuresis can be taken into consideration. The rate of occurrence of enuresis was analyzed in all the drugs with their respective doses, but the significant values were found only for SV 200 mg.

Conclusion: This study shows the possibility of enuresis in LEV and SV treatment with a significant difference in SV. Furthermore, it showed a relation between the duration of treatment and the occurrence of enuresis.

Keywords: Enuresis, Antiepileptics, Adverse drug reaction, Children.

© 2022 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). DOI: http://dx.doi.org/10.22159/ajpcr.2022.v15i11.42923. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr

INTRODUCTION

Epilepsy is characterized by continuous seizures, which are short episodes of involuntary movement that may involve a part of the body (partial) or the entire body (generalized) and are followed by loss of consciousness and control of bowel or bladder function. Epilepsy is uniformly distributed around the world. There are no racial, geographical, or social class boundaries. It occurs in both sexes, at all ages, mostly in childhood, adolescence, and increasingly in aging populations. It is considered one of the most common childhood brain disorders. Patients with epilepsy are now treated with pharmacotherapy, occasionally with neurosurgical techniques, as well as with psychological and social support. One of the underreported adverse effects of antiepileptic drugs (AEDs) is enuresis [1,2].

Enuresis is commonly known as bed-wetting. Anti epileptics cause confusion or changes in behavior as a side effect which is associated to be the cause of enuresis in those under treatment with AED’s. Some of the three main symptoms of enuresis included are frequent bed-wetting, wetting in the clothes, and wetting at least twice a week continuously for 3 months [3]. Several mechanisms are known to have caused enuresis, out of which bladder capacity and nocturnal urine production are considered to be concurring in the highest degree [4,5].

Sodium valproate (SV) is effective and well-tolerated for the treatment of epilepsy and mood disorders in children. Several reported cases of SV-induced enuresis were noted in epileptic patients. No alternative medication has been suggested to manage this problem [6,7]. Carbamazepine which had been used previously to treat nocturnal enuresis [8] however, is said to cause enuresis by a recent study [9]. Levetiracetam (LEV), a novel AED has recently been approved as an add-on treatment for various seizure types in epilepsy populations including children is reported by FDA to cause enuresis. But very few studies are conducted based on it [10,11]. Thus, this study is proposed based on the assumption that enuresis may occur in children on treatment with SV, LEV, and carbamazepine thereby, creating awareness to physicians, other health care professionals, and the patient’s caregiver about this underreported ADR. The major objectives of the study are to assess the incidence of urinary frequency and enuresis in children with epilepsy who are on AEDs treatment such as carbamazepine, SV, and LEV. Furthermore, to compare the rate of enuresis in patients on treatment with carbamazepine, SV, and LEV.

METHODOLOGY

The study was conducted in a tertiary care hospital in Coimbatore for 6 months with a sample size of 32 patients. The Ethical Committee of the hospital approved the study [Ref: EC/AP/711/06/2019]. Both inpatients and outpatients between the age group 5–18 years of age were included also, patients previously diagnosed with epilepsy who are on monotherapy and polytherapy with SV or carbamazepine or LEV were enrolled. Patients having any current urinary complication or urogenital abnormalities past 3 months before admission were excluded from the study. The enrolled patients were grouped under six categories (Fig 1).

Currently, for the treatment in place of carbamazepine, oxcarbazepine (OX) is given due to its lesser side effects. OX is the keto analogue of carbamazepine. It was developed to mimic the efficacy of carbamazepine while minimizing the side effects of the original drug [12,13]. Hence, the drug was changed from carbamazepine to OX. Informed consent was obtained from the patients included in the study. Details on demographics, medication prescribed, the dose of the drugs, and duration were noted. Assessment of the enuresis was done by the
questionnaire formulated as per NICE guidelines during the review visit. Those patients who failed to come for a second review were reminded over the telephone regarding their review and follow-up. The collected data was finally analyzed using SPSS software version 2.0.

RESULTS

This study included a total of 44 patients but only 34 patients came for review at the requested period. Among the 34, 55.9% (19) belonged to the age group 5–≤9, 38.2% (13) to 10–≤14, and 5.9% (2) in the 15–≤19 age group. The study consisted of a majority of males with 61.8% (21) and a minor female population of 38.2% (13) (Table 1). The duration of treatment showed a major difference ranging from 3 months to 2 years. With a majority of 39.1% (14) in 1–3 months and a minority of 5.8% (2) in 7–9 months.

Assessment of the questionnaire

1. **Q1** Is the child occasionally or regularly wet at night?
   - In this 35.3% (12) responded as yes and 64.7% (22) as no. This showed euresis positive cases in 12 members. Furthermore, the cases were all of the monotherapy.

2. **Q2** Does the child wake after wetting?
   - Deeper sleep and increased slow brain-wave activity are potential reasons for NE. In question Q2 only 14.7% (5) did not wake up after wetting and the remaining 85.3% (29) got up. This initiated a possibility that increased sleep depth may be a reason to cause enuresis.

3. **Q3** Is the wetting: Primary/Secondary
   - The wetting was found to be secondary 35.3% (12) of the total population which included the 12 positive cases.

4. **Q4** Does the child get up to void during the night?
   - About 38.2% of the patient did not get up to void which makeup 13 persons out of 34 cases. Out of the 12 positive enuresis cases, 7 (20.6%) cases were shown to get up once a night for urination whereas five did not get up to urinate.

5. **Q5** Volume of wetting
   - Seven out of 34 wets just the nightwear as per assessment that constitutes 20.6% of the population and five of them seems to have voided with a patch the size of a dinner plate that makes up 14.7% of the total population. This showed the significance of wetting in persons induced with enuresis due to the drug.

6. **Q6** Time of wetting:
   - The persons affected are shown to have voided later in the night which included 35.3% (12) of the positive cases.

7. **Q7** Size of the morning void:
   - The size of the morning void was found to be larger in 11 cases (32.3%), 7 of which were positive of enuresis. It could be taken as an increased bladder activity due to the intake of the drug.

8. **Q8** Color of the morning void:
   - About 64.7% (22) had dilute urine during morning void and 35.3 (12) of them had concentrated. Those reported to have enuresis seem to have diluted urine may be due to a high intake of water and increased bladder activity. However, the cases varied and did not show a correct assessment of intake of fluids time.

9. **Q9** When was the last time the child drank water/other fluids?
   - Analysis showed 16 of them drank fluids after breakfast of which five had drunk a few minutes before assessment similar in the case after lunch including three persons. However, this question was not relevant in assessing the thirst as a whole.

10. **Q10** What time does the child go to sleep?
    - The assessment showed a maximum of 14 persons each in 8–9 pm and 9–10 pm but was not a substantial question to assess the depth of sleep.

11. **Q11** Does the child void before going to bed?
    - About 79.4% of the people voided before going to bed with 20.6% not getting up to void as analyzed by Q11. The positive cases are shown to have voided before going to bed and still bed wetted later at night, hence it’s an indication of increased urine production in those cases.

Chi-square test assessment

- Assessment of the relation between two variables showed no significance in age versus drugs given (0.373) and gender versus drugs given (0.47). The significance of age versus assessment and gender versus assessment questions also showed they are independent of each other with values all >0.05.

- The assessment of age and gender versus the questionnaire also showed not much significance. However, the analysis of duration versus assessment showed significance in Q1, Q2, Q3, Q4, Q5, Q6, and Q11 which indicated a relationship between the duration of treatment and the occurrence of enuresis.

- The analysis of drugs prescribed vs. assessment questions showed potent significance in Q1, Q2, Q3, Q4, Q5, Q6, Q8, and Q11 with that the hypothesis that the prescribed drugs can cause enuresis can be taken into consideration (Table 2). Furthermore, it showed the occurrence of enuresis in two drugs that is LEV and SV.

Analysis of variance (ANOVA) assessment

- All the questions were formulated from the NICE guidelines up to 19 years of age, used to analyze the occurrence of enuresis in children.

Table 1: Demographic distribution of the study population

| Demographics | No. of patients | Percentage |
|---------------|----------------|------------|
| Age           |                |            |
| 5–≤9          | 19             | 55.9       |
| 10–≤14        | 13             | 38.2       |
| 15–≤18        | 2              | 5.9        |
| Total         | 34             | 100.0      |
| Gender        |                |            |
| Male          | 21             | 61.8       |
| Female        | 13             | 38.2       |
| Total         | 34             | 100.0      |

Table 2: Duration versus assessment question Chi-square analysis

| S. No. | Questions                                                       | p-value |
|--------|                                                               |         |
| 1.     | Is the child occasionally or regularly wet at night?            | 0.00    |
| 2.     | Does the child wake after wetting?                              | 0.202   |
| 3.     | Is the wetting primary/secondary                                | 0.00    |
| 4.     | Does the child get up to void during the night?                 | 0.00    |
| 5.     | The volume of wetting:                                         | 0.01    |
| 6.     | Time of wetting:                                               | 0.00    |
| 7.     | Size of morning void:                                         | 0.33    |
| 8.     | Color of morning void:                                        | 0.05    |
| 9.     | When was the last time the child drank water/any other fluids? | 0.45    |
| 10.    | What time does the child go to sleep?                          | 0.19    |
| 11.    | Does the child void before going to bed?                       | 0.01    |
To check the rate of enuresis occurrence in different drug groups, each drug with their prescribed doses were analyzed by one-way ANOVA. However, the significant result was only found in the case of SV 200 mg (Table 3).

- The dose SV 200 mg was prescribed for all the seven cases presented with enuresis at the requested time also the patients were all under the treatment for 6 months–2 years.

**DISCUSSION**

This study provides an insight into the rare ADR of AEDs used frequently in children. Due to the irrelevance of bedwetting as a habit outgrown with age it is overlooked in most cases and at times is underreported due to embarrassment. Suman and Gosavi [14] in children visiting pediatric OP at tertiary care teaching hospital with complaints of epilepsy and who were prescribed with AED’s were evaluated for ADR In that AEDs such as nocturnal enuresis and increased frequency of micturition were observed in 4.4% of patients, especially in VPA therapy. The study also revealed nocturnal enuresis and increased frequency of micturition as a less reported ADR. Many of the studies show more prevalence in males than in females. Linehan and Kerr [15] showed males are reported more with seizures frequently than females (6.5% vs 1.7%; p<0.001). Polystery was only seen in two cases 2.9% each, one constituting a combination of LEV- SV and another SV-OX. OX-LEV combination was not prescribed during the study course. During the past 20 years, the use of monotherapy remains the mainstay of treatment among pediatric seizures. Raj et al, [16] study showed 70–90% of newly diagnosed common forms of epilepsy can be controlled using a single agent.

Assessment of the questionnaire showed the occurrence of enuresis in monotherapy patients also increased sleep depth pattern. Esposito et al, (2013) [17] evaluated the presence of sleep disturbances in a population of children affected by nocturnal enuresis, it showed that sleep could be strongly altered, thus affirming the hypothesis that nocturnal enuresis tends to alter the sleep architecture of affected children, or it could itself be the consequence of an abnormal sleep structure. However, since the present study did not include any sleep depth measurement such as polysomnography in the study we couldn’t say for sure it is a possible cause.

The occurrence of enuresis was observed to be secondary. Ramakrishnan and Krishnan [18] proposed the following details of secondary enuresis in their review study. Secondary nocturnal enuresis (SNE) accounts for about one-quarter of children with bedwetting. By age 10 years, up to 8% of children are estimated to develop SNE. The reported etiologies are sleep problems, bladder problems, medical conditions, psychological stress, and hormone problems.

Out of the 12, positive enuresis cases in this study were shown to get up once a night for urination, whereas live did not get up to urinate. Zrubavel et al, [19] conducted a study including 32 children who were referred with enuresis in a hospital study. The study concludes that children with NE slept significantly worse than did the controls subjects.

**Table 3: Assessment of rate of occurrence of enuresis in different drug groups – one way ANOVA test**

| Drug  | Question no. | p-value |
|-------|--------------|---------|
| SV200 | Q1           | 0.000   |
| SV200 | Q2           | 0.000   |
| SV200 | Q3           | 0.000   |
| SV200 | Q4           | 0.002   |
| SV200 | Q5           | 0.000   |
| SV200 | Q6           | 0.000   |
| SV200 | Q7           | 0.022   |
| SV200 | Q8           | 0.001   |
| SV200 | Q9           | 0.046   |
| SV200 | Q10          | 0.843   |
| SV200 | Q11          | 0.009   |

and were reported to get up at least once at night to urinate. According to their study, this sleep fragmentation leads to an increased arousal threshold, which, in turn, leads to failure to respond to full-bladder signals and additional bedwetting.

A significant increase in urine volume was also observed during this study. Nevéus [20] conducted a study to measure the volume of urine in enuretics using anamnestic data and voiding charts, including measurement of nocturnal urine production. The study concludes that the amount of urine voided in bed in enuretics children is found to be highly correlated to nocturnal urine production but only rarely large enough to represent the voiding of a full bladder.

Thiedk [21] says that though in most studies, sleep electrolytes have demonstrated no differences or only nonspecific changes in children with and without nocturnal enuresis. But when surveyed, parents consistently maintain that their children with nocturnal enuresis are “deep sleepers,” and they seem to wet later in the night compared with their offspring who are non-bed-wetter. The same was observed in the positive cases of the study subjects.

Chi-square assessment showed a significant relationship between the drugs given and enuresis of which SV was predominant. Reza et al, (2018) [6] which evaluated the effect of sodium evaporate monotherapy on the enuresis and urinary frequency in children with epilepsy and compared it with carbamazepine showed there was no statistically significant difference found between demographic parameters such as age and gender. But a significant value was obtained with the disease duration (0.09%). Hence, it could be concluded that a longer duration of treatment can induce the chance of occurrence of enuresis. Apart from that, it could be a secondary cause induced due to the effect of drugs in the renal tubules and sleep pattern resulting in increased thirst and deep sleep [22-25].

Gosavi et al, [7] concluded that enuresis was an underreported ADR of SV. Although the exact cause of this ADR was not established, it can be attributed to increased thirst and/or increased depth of sleep.

Egger et al, (1981) [26] emphasized enuresis as a possible side effect of SV treatment. Herranz et al, [27] also evaluated the adverse event profile of valproate in children with epilepsy mentioned that 5 out of 88 children (6%) developed nocturnal enuresis.

Recent studies have shown that there might be a relation between consumption of SV and urinary complications such as enuresis, polyuria, and urine incontinence. According to the pieces of literature, these side effects are more likely to occur in patients who require dosage increase [28,29].

Despite these reports, there is a lack of solid shreds of evidence on the association of urinary complications with SV. The limitation of this study is that this study did not include the measurement of sleep depth and the measurement of the volume of morning void. Also, the assessment questionnaire to measure the thirst factor was insufficient. Hence, we could not strongly emphasize enuresis as a known side effect of this drug, but it showed the possibility of occurrence in LEV and SV which could be taken as the base for further future research involving a larger subject and longer duration of the study.

**CONCLUSION**

Enuresis is a rare side effect of AEDs. It is considered to be a condition that is outgrown with age. The underreporting of this ADR is yet another factor that makes it an unnoticed side effect, owing to the embarrassment of the situation. Since antiepileptics are drugs that could not be stopped or which sometimes need to be taken for a long duration till epilepsy relapses the occurrence of enuresis in these situations can be troublesome on both the lives of the child and the parent. This study shows the possibility of enuresis occurrence in LEV and SV treatment with a significant difference in SV. No occurrence was...
noted in the case of OX. Since there is no scoring pattern this extend of enuresis could not be established however, the statistical analysis showed a relation between the prescribed drugs and the association of enuresis occurrence in SV treatment. A significant result was obtained for SV dose 200mg that constituted seven cases out of the 12 positive cases. Various hypotheses have been proposed towards the etiologies of drug-induced enuresis primly thirst and sleep disturbance was noted. However, this study did not focus on any special mechanism to measure sleep depth or thirst. Hence further studies enumerating the association of sleeping patterns and increased thirst with SV treatment are needed to create a solid awareness of this adverse drug reaction.

ACKNOWLEDGMENT
We thank Dr. Rajendiran, consultant pediatrician, Koval Medical Center, and Hospital for his timely advice and support. We would also like to extend our heartfelt gratitude to Dr. S.Shalini, HOD of Pharmacy Practice, RKMCH College of Pharmacy Coimbatore for her in prompt guidance.

CONFLICT OF INTEREST
The author(s) declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

AUTHORS CONTRIBUTIONS
Ms. Arya Sathyan is the main researcher and corresponding author of the study. Ms. Reshma Scaria, M pharm is the co-author responsible for helping out with data collection, analysis, and article preparation.

AUTHORS FUNDING
The author(s) received no financial support for the research, authorship, and/or publication of this article.

REFERENCES
1. Staffstrom CE, Carmant L. Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harb Perspect Med 2015;5:a022426.
2. Anna R, Salvatore M, Renzo G. Antiepileptic drug treatment in children with epilepsy. CNS Drugs 2015;29:847-63.
3. Arda E, Cakiroglu B, Thomas DT. Primary nocturnal enuresis: A review. Nephrourol Mon 2016;8:e35809.
4. Baird DC, Sechusen DA, Bode DV. Enuresis in children: A case-based approach. Am Fam Physician 2014;90:560-8.
5. Soren R, Konstantinos K. Epidemiology of epilepsy in developed countries. In: Benbadis SR, Beran RG, Berg AT, Engel J Jr., Galanopoulos AS, Kaplan PW, editors. Atlas of Epilepsies. Berlin, Heidelberg: Springer; 2010. p. 51-6.
6. Raj HD, Sylvia A, Chidambaramathan S, Nirmala P. Monotherapy and polytherapy in paediatric seizures: A prospective, observational study in a tertiary care teaching hospital. Int Arch Integer Med 2017;4:97-104.
7. Esposito M, Gallai B, Parisi L, Roccella M, Marotta R, Lavano SM, Carotenut OG. Primary nocturnal enuresis as a risk factor for sleep disorders: An observational questionnaire-based multicenter study. Neuropsychiatr Dis Treat 2013;9:437-43.
8. Ramakrishnan K, Krishnan K. Evaluation and treatment of enuresis. Am Fam Physician 2008;78:489-96.
9. Zrubavel CV, Kushnir B, Kushnir S, Sadeh A. Sleep and sleepiness in children with nocturnal enuresis. Sleep 2011;34:191-4.
10. Neveus T. The amount of urine voided in bed by children with enuresis. J Pediatr Urol 2015;11:133-7.
11. Thiedk CC. Nocturnal enuresis. Am Fam Physician 2003;67:1499-506.
12. Vande J, Vande WC, Van SP, De GA, Raes A, Donckerwolcke R. Nocturnal polyuria is related to 24-hour diuresis and osmotic excretion in an enuresis population referred to a tertiary center. J Urol 2007;178:2630-5.
13. Pomeranz A, Abu-Kheat G, Korzets Z, Wolach B. Night-time polyuria and urine hypo-osmolality in enuretics identified by nocturnal sequential urine sampling: Do they represent a subset of relative ADH-deficient subjects? Scand J Urol 2000;34:199-202.
14. Dehoorne JL, Raes AM, Van LE, Hovebeke P, Vande Walle JG. Desmopressin resistant nocturnal polyuria secondary to increased nocturnal osmotic excretion. J Urol 2007;176:749-53.
15. Aikawa T, Kasahara T, Uchiyama M. The arginine vasopressin secretion profile of children with primary nocturnal enuresis. Eur Urol 2010;58:31-6.
16. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-81.
17. Herranz JL, Artiega R, Armijo JA. Side effects of sodium valproate in monotherapy controlled by plasma levels: A study in 88 pediatric patients. Epilepsia 1982;23:203-14.
18. Yamak WR, Hmainess G, Makke Y, Sabbagh S, Arabi M, Beydoun A. Valproate-induced enuresis: A prospective study. Dev Med Child Neurol 2015;57:737-41.
19. Malik AM, Usmani A. Day time urinary incontinence due to valproate in a patient with idiopathic generalized tonic-clonic seizures. J Med Case Rep 2013;3:53-5.